S E P T E M B E R 2 0 1 5 • O P T O M E T R I C M A N A G E M E N T . C O M
S 17
in hypochlorous acid has been shown to be cytotoxic
in numerous in vitro studies. Also, an impure form of
hypochlorous acid has been commercially available for
nearly 200 years without serious uptake by the medical
community.
Ron was quite intrigued with the properties of this
pure form of hypochlorous acid. It has tremendously
more antimicrobial activity than the historical product
and a better in vitro safety profle.
Post discovery of Neutrox, he focused on developing
a new class of antimicrobials based on chlorotaurine
chemistry, which he calls Aganocides®. Aganocides are
designed to be used in conditions in which more sus-
tained antimicrobial action against microbes is needed.
Today, NovaBay Pharmaceuticals is commercializing
and developing non-antibiotic, anti-infective products
that address unmet therapeutic needs of the global topi-
cal antimicrobial market. Te company has two distinc-
tive product categories: its Aganocide compounds and
the Neutrox family of products, which include the com-
mercial prescription products Avenova Daily Lid & Lash
Hygiene and NeutroPhase® Skin and Wound Cleanser.
In 2014, NovaBay decided to focus its R&D; eforts on
eye care. Avenova is the frst of many innovations from
NovaBay. In June 2015, NovaBay introduced its game-
changing intelli-Case hydrogen peroxide system, an
FDA-cleared high-tech, easy-to-use device for use with
hydrogen peroxide disinfection solutions to sterilize sof
and rigid gas permeable contact lenses. No more guess
work with intelli-Case. Intelli-Case has the ability to as-
sess the condition of hydrogen peroxide and its platinum
neutralizer and provide electronic feedback to the cus-
tomer. See more on intelli-Case at http://novabay.com/
technology/Intelli-Case.
Additional exciting pipeline products will be intro-
duced in early 2016
S P O N S O R E D B Y N O V A B A Y
OPTOME TRIC MANAGEMENT CORPORATE PROFILE